At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 39 enrolled
Drug / intervention
Melatonin +1 moredrug
Likely dose
Melatonin 8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Melatonin Supplementation and the Metabolic Syndrome: A Phase II Crossover Design Clinical Trial
In Brief
A Phase 2 clinical trial evaluating Melatonin and Placebo for Metabolic Syndrome. Completed, enrolled 39 participants across 2 sites.
Detailed Summary
This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedDec 2009
Primary CompletionJun 2012
Study CompletionJul 2013
TodayJul 2026
First PostedDec 24, 2009
Enrollment StartJul 1, 2009
Primary CompletionJun 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.5 years ago
Interventions
Melatonindrug
8 mg dose of Melatonin
Placebodrug
Placebo